Novel Therapeutic Approaches to Tuberculosis  (C7)
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Novel Therapeutic Approaches to Tuberculosis (C7)

on

  • 191 views

 

Statistics

Views

Total Views
191
Views on SlideShare
189
Embed Views
2

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 2

http://www.mdconferencefinder.com 2

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Novel Therapeutic Approaches to Tuberculosis (C7) Document Transcript

  • 1. SUNDAY, MARCH 30 MONDAY, MARCH 31 Keynote Address Charles N. Serhan, Brigham and Women's Hospital, USA Regulation of Acute Inflammation and Resolution : Lessons from Lipid Mediators Inflammation: Balance between Bacterial Control and Immunopathology David M. Tobin, Duke University Medical Center, USA Eicosanoid Balances Determine TB Disease Progression Andrea M. Cooper, Trudeau Institute, USA Regulation of Pathology Helen A. Fletcher, University of Oxford, UK Role of Myeloid Signatures in the Prediction of Active Tuberculosis Short Talk(s) Chosen from Abstracts Strategies to Ameliorate Lung Damage Paul T. Elkington, University of Southampton, UK Targeting Matrix Metalloproteinase Activity to Reduce Immunopathology Samuel M. Behar, Brigham and Women's Hospital, USA Tissue-Protective Activities of Adaptive Immunity Speaker to be Announced Short Talk Chosen from Abstracts Poster Session 1 TUESDAY, APRIL 1 Novel Antimicrobial Strategies Lalita Ramakrishnan, University of Washington, USA Overcoming Environmentally-Induced Drug Tolerance Terry Roemer, Merck, USA Exploiting Chemical and Genetic Synergies to Improve Antibiotic Activity William R. Bishai†, Johns Hopkins School of Medicine, USA KRITH Immunomodulation during Therapy Speaker to be Announced Short Talk(s) Chosen from Abstracts Host-Directed Antimicrobial Therapies Kanury V. S. Rao, International Centre for Genetic Engineering and Biotechnology, India Manipulating Host-Pathogen Crosstalk to Treat TB Infection Daniel Kalman, Emory University, USA Repurposing Host-Directed Drugs to Treat Infectious Disease Robert J. Wilkinson, University of Cape Town, South Africa The Interaction between Antimicrobial and Adjunctive Therapies and the Immune Response to Tuberculosis Short Talk(s) Chosen from Abstracts Poster Session 2 WEDNESDAY, APRIL 2 Targeting Persistent Bacterial Populations Tawanda Gumbo, UT Southwestern Medical Center, USA Accelerating the Kill of Tuberculosis Persisters: The Interaction of Drug Concentration and Novel Bacterial Complex Adaptive Systems Stewart T. Cole, École Polytechnique Fédérale de Lausanne, Switzerland Eradicating Persistent Bacteria Christopher M. Sassetti, University of Massachusetts Medical School, USA Bacterial Adaptations to the Host Environment Speaker to be Announced Short Talk(s) Chosen from Abstracts Therapy for Latent TB Infection Gavin J. Churchyard, Aurum Institute, South Africa Community/Population-Based Interventions for LTBI Peter Andersen, Statens Serum Institut, Denmark Development of an LTBI Vaccine David M. Margolis, University of North Carolina at Chapel Hill, USA Eradication of Latent Pathogens: Lessons from HIV Short Talk(s) Chosen from Abstracts Poster Session 3 THURSDAY, APRIL 3 Immunotherapy for Active Disease Alan Sher, NIAID, National Institutes of Health, USA Understanding and Modulating TB Disease Anne O'Garra, MRC National Institute for Medical Research, UK Biology and Therapeutic Potential of IL-10 Modulation Gilla Kaplan†, Public Health Research Institute, UMDNJ, USA Changing the Course of TB Pathogenesis and Treatment Steven Holland, NIAID, NIH, USA Genetic Determinants of Reactivation Short Talk(s) Chosen from Abstracts Therapeutic Vaccines Douglas Lowrie†, Fudan University, China Development of a Vaccine for the Treatment of MDR TB Geneviève Inchauspe, Transgène, France Immune Modulation in Latent and Active Disease through Vaccination Rhea N. Coler, Infectious Disease Research Institute, USA Preclinical and Clinical Testing of a Therapeutic Vaccine Short Talk Chosen from Abstracts FRIDAY, APRIL 4 * Session Chair  † Invited but not yet accepted     Program current as of April 5, 2013. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit www.keystonesymposia.org/14C7. KEYSTONE SYMPOSIA on Molecular and Cellular Biology Novel Therapeutic Approaches to Tuberculosis (C7) March 30-April 4, 2014 •  Keystone Resort •  Keystone, Colorado, USA Scientific Organizers: Christopher M. Sassetti and Thomas G. Evans Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation Global Health Travel Award Deadline: October 29, 2013 / Abstract & Scholarship Deadline: December 3, 2013 / Abstract Deadline: January 7, 2014 / Discounted Registration Deadline: January 29, 2014